Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 132

Results For "cost"

1356 News Found

JB Chemicals PAT jumps by 101% to Rs101 Cr
News | June 15, 2021

JB Chemicals PAT jumps by 101% to Rs101 Cr

The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020


Trials of three more vaccines are in advanced stage: Modi
News | June 08, 2021

Trials of three more vaccines are in advanced stage: Modi

The Prime Minister announced that 21st June onwards, the Government of India will provide free vaccines to all Indian citizens above 18 years of age


Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
News | June 02, 2021

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.


Govt. to give 12 Cr COVID vaccine doses in June 2021
News | May 31, 2021

Govt. to give 12 Cr COVID vaccine doses in June 2021

7.94 crore doses were made available to the states in May 2021


Margins impacted by high expenses for Pfizer: ICICI Securities
News | May 31, 2021

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY


Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
Drug Approval | May 31, 2021

Cadila Healthcare’s margin supported by lower R&D : ICICI Securities

India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact


Sun Pharmaceutical’s internals remain strong: ICICI Securities
News | May 31, 2021

Sun Pharmaceutical’s internals remain strong: ICICI Securities

US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio


Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
News | May 31, 2021

Multiple catalysts ahead for Cadila Healthcare: HDFC Securities

Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.


Remdesivir demand was exaggerated: Dr. Sharvil Patel
News | May 28, 2021

Remdesivir demand was exaggerated: Dr. Sharvil Patel

Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines


Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21
News | May 27, 2021

Strides Pharma Science posts consolidated PAT of Rs. 46.08 Cr in Q4FY21

Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21